Virchows Archiv最新文献

Glycoprotein nonmetastatic melanoma protein b immunohistochemistry can be a useful ancillary tool to diagnose subependymal giant cell astrocytoma. 糖蛋白非转移性黑色素瘤蛋白b免疫组化可作为诊断室管膜下巨细胞星形细胞瘤的辅助工具。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2025-05-27 DOI: 10.1007/s00428-025-04110-9

Marián Švajdler, Marek Brousil, Jiří Soukup, David Netuka, Petra Kašparová, Boris Rychlý, Tomáš Jirásek, Michal Hendrych, Mihaela Farcas, Kristýna Pivovarčíková, Tomáš Vaněček, Petr Martínek, Roman Mezencev

{"title":"Glycoprotein nonmetastatic melanoma protein b immunohistochemistry can be a useful ancillary tool to diagnose subependymal giant cell astrocytoma.","authors":"Marián Švajdler, Marek Brousil, Jiří Soukup, David Netuka, Petra Kašparová, Boris Rychlý, Tomáš Jirásek, Michal Hendrych, Mihaela Farcas, Kristýna Pivovarčíková, Tomáš Vaněček, Petr Martínek, Roman Mezencev","doi":"10.1007/s00428-025-04110-9","DOIUrl":"https://doi.org/10.1007/s00428-025-04110-9","url":null,"abstract":"Subependymal giant cell astrocytoma (SEGA) is a World Health Organization Central Nervous System grade 1 tumor, strongly associated with tuberous sclerosis complex (TSC). Recent research indicates that Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB), regulated by microphthalmia (MiT) family transcription factors may also be modulated by loss-of-function mutations in TSC1/2. We evaluated GPNMB as a diagnostic marker of subependymal giant cell astrocytoma (SEGA). A total of 11 patients with SEGA were included in the study. The control group comprised 185 primary central nervous system tumors, including high-grade and low-grade gliomas and glioneuronal/neuronal tumors. Strong and diffuse (≥ 50% of tumor cells) GPNMB expression was present in all SEGAs. In contrast, TTF-1 expression was detected in nine SEGAs, resulting in a sensitivity of 81.8%. Among the control group, 77 cases (41.6%) were negative for GPNMB and 102 (55.1%) cases were scored as > 1% < 50% positive. Only six control tissues (3.2%) showed diffuse and strong GPNMB expression. Among the tumors with strong GPNMB expression, there were three glioblastomas (GBMs) with morphology potentially mimicking SEGA but lacking TSC1, TSC2, or MTOR mutations. Using a cutoff of diffuse (≥ 50%) and strong positivity, GPNMB demonstrated 100% sensitivity (95% confidence interval: 74.1%-100%) and 96.8% specificity (95% confidence interval: 93.1%-98.5%) for diagnosing SEGA.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FGFR3 amplification is predictive of poor prognosis in esophageal squamous cell carcinoma patients. FGFR3扩增可预测食管鳞状细胞癌患者预后不良。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2025-05-26 DOI: 10.1007/s00428-024-03884-8

Xiang Wang, Jie Huang, Chen Xu, Lili Zhang, Jieakesu Su, Jia Liu, Licheng Shen, Lijuan Luan, Yingyong Hou

{"title":"FGFR3 amplification is predictive of poor prognosis in esophageal squamous cell carcinoma patients.","authors":"Xiang Wang, Jie Huang, Chen Xu, Lili Zhang, Jieakesu Su, Jia Liu, Licheng Shen, Lijuan Luan, Yingyong Hou","doi":"10.1007/s00428-024-03884-8","DOIUrl":"https://doi.org/10.1007/s00428-024-03884-8","url":null,"abstract":"Identification and verification of clinically actionable molecular variations to refine currently adopted risk-stratified treatment strategy for esophageal squamous cell carcinoma (ESCC) is urgently needed. Here, we evaluated FGFR3 amplification status by fluorescence in situ hybridization (FISH) performed on tissue microarrays and its prognostic value in 526 ESCC patients. FGFR3 amplification was found in 3.0% (16/526) of ESCC patients enrolled in this study cohort. Intratumor heterogeneity and metastatic heterogeneity of FGFR3 amplification were found in 10% (2/20) and 40% (2/5) FGFR3 amplified ESCC cases, respectively. No statistically significant associations were found between FGFR3 amplification status and common clinicopathological features. Survival analyses demonstrated that FGFR3 amplification was associated with a worse disease-free survival (DFS) and overall survival (OS) (DFS, P = 0.008; OS, P = 0.027). Univariate and multivariate analyses revealed that invasive depth was significantly associated with DFS (P = 0.001, HR: 1.498, 95% CI: 1.172-1.914) and OS (P = 0.002, HR: 1.482, 95% CI: 1.159-1.894), and FGFR3 amplification was significantly associated with DFS (P = 0.020, HR: 2.065, 95% CI: 1.120-3.808) and tend to associate with OS (P = 0.070, HR: 1.756, 95% CI: 0.954-3.233). Furthermore, when patients were stratified into stage I-II group and stage III-IV group, the adverse effect of FGFR3 amplification on prognosis was presented in stage III-IV patients (DFS, P = 0.0047; OS, P = 0.029) rather than stage I-II patients (DFS, P = 0.46; OS, P = 0.53), indicating that the prognostic value of FGFR3 amplification may relying on clinical stage. Our findings might provide a better understanding of the FGFR3 amplification status in ESCC patients and add further insights into its potential prognostic value.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dermatomyofibromas harbor PDGFRB mutations - another tyrosine kinase-driven neoplasm. 皮肌瘤携带PDGFRB突变-另一种酪氨酸激酶驱动的肿瘤。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2025-05-19 DOI: 10.1007/s00428-025-04128-z

Uta Flucke, Laura S Hiemcke-Jiwa, Joost M van Gorp, Don Hayes, Marieke M B Seyger, Marco J Koudijs, Lennart A Kester, Sjoerd van Helvert, Remco T P van Cruchten

{"title":"Dermatomyofibromas harbor PDGFRB mutations - another tyrosine kinase-driven neoplasm.","authors":"Uta Flucke, Laura S Hiemcke-Jiwa, Joost M van Gorp, Don Hayes, Marieke M B Seyger, Marco J Koudijs, Lennart A Kester, Sjoerd van Helvert, Remco T P van Cruchten","doi":"10.1007/s00428-025-04128-z","DOIUrl":"https://doi.org/10.1007/s00428-025-04128-z","url":null,"abstract":"Platelet-derived growth factor receptor beta (PDGFRB) is one of the numerous members of the receptor tyrosine kinase protein family. When altered, it is known to be the driver mutation in different mesenchymal neoplasms, such as pericytic tumors, inflammatory myofibroblastic tumor, and sarcomas with myogenic differentiation. We investigated seven dermatomyofibromas for the presence of a PDGFRB mutation. Patients were 6 females and 1 male. Ages ranged from 2 to 59 years. Neoplasms were located in the shoulder (2), neck (2), upper arm (1), knee (1), and calf (1). Clinically, they appeared as ill-defined plaques. Complete excision was performed in four cases. In three cases, only a biopsy was taken. Histomorphologically, these dermal ill-defined tumors consisted of fascicles of slender myofibroblastic cells oriented often parallel to the epidermis. Their nuclei were monomorphic and elongated, and the cytoplasm was inconspicuous. Involvement of the superficial subcutis was seen in four cases. Immunohistochemically, neoplasms expressed SMA (5/7), focally desmin (1/5), and CD34 (4/6), while S100 was lacking (0/7). By DNA or RNA sequencing, PDGFRB activating mutations were identified in 6/7 tumors. Four neoplasms harbored a mutation in exon 12 encoding for the juxtamembrane domain and 2 neoplasms in exon 14 encoding for the tyrosine kinase domain. Sequencing analyses results highlight that these benign skin tumors belong to the broad spectrum of tyrosine kinase-driven neoplasms.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Underdiagnosis of positive resection margins and synchronous peritoneal metastases in locally advanced colon cancer: histopathological reassessment of primary resection in the COLOPEC trial. 局部晚期结肠癌阳性切除边缘和同步腹膜转移的诊断不足：COLOPEC试验中原发性切除的组织病理学重新评估。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2025-05-16 DOI: 10.1007/s00428-025-04065-x

E S Zwanenburg, D D Wisselink, C E L Klaver, J D W van der Bilt, J G van den Berg, L L Kodach, I D Nagtegaal, P J Tanis, P Snaebjornsson

{"title":"Underdiagnosis of positive resection margins and synchronous peritoneal metastases in locally advanced colon cancer: histopathological reassessment of primary resection in the COLOPEC trial.","authors":"E S Zwanenburg, D D Wisselink, C E L Klaver, J D W van der Bilt, J G van den Berg, L L Kodach, I D Nagtegaal, P J Tanis, P Snaebjornsson","doi":"10.1007/s00428-025-04065-x","DOIUrl":"https://doi.org/10.1007/s00428-025-04065-x","url":null,"abstract":"The aim of this study was to perform histopathological reassessment of primary resections of locally advanced colon cancer (CC) within a randomized controlled trial, with specific focus on surgical margins and synchronous locoregional peritoneal metastases (SL-PM), and to provide learning points for both surgeons and pathologists. All histopathological slides of patients with c/pT4N0-2M0 or perforated CC included in the COLOPEC trial were reassessed and correlated with surgical reports. The COLOPEC trial originally determined the value of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC). Frequency of positive margins (R +), R + subtypes, and SL-PM and the association with 5-year peritoneal recurrence were analyzed. Histopathological slides of 199 patients were reassessed. R + was present in 28 patients (14.1%), of which 8 occurred at the site of adhesiolysis (originally classified as pT4a in 6). SL-PM was present in 11 cases (5.5%), of which 9 were not recognized or misclassified. Both R + and SL-PM were associated with 5-year peritoneal metastases in cox regression analysis (HR 2.38, 95% CI 1.12-5.04 and HR 5.98, 95% CI 2.69-13.29, respectively). Of 9 patients with peritoneal recurrences detected during re-exploration at 5-8 weeks after primary tumor resection for intended HIPEC, 5 demonstrated either R + and/or SL-PM. This study brings to light previously unnoticed but clinicopathologically relevant aspects of CC pathology retaining to underdetected SL-PM and new R + types. Underrecognition until now probably relates to the complexity of advanced CC specimens, poor communication between surgeons and pathologists, and the low incidence among high volumes of CC specimens. Trial registration: NCT02231086 (Clinicaltrials.gov).","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endometrial stromal tumor with whorling and GREB1::CTNNB1 fusion: expanding the knowledge on a recently described entity. 子宫内膜间质瘤与whorling和GREB1::CTNNB1融合：扩大对最近描述的实体的认识。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2025-05-14 DOI: 10.1007/s00428-025-04127-0

Antonio Travaglino, Damiano Arciuolo, Susanna Ronchi, Antonio Raffone, Isabella Giovannoni, Sabina Barresi, Jvan Casarin, Gian Franco Zannoni, Rita Alaggio, Stefano La Rosa

{"title":"Endometrial stromal tumor with whorling and GREB1::CTNNB1 fusion: expanding the knowledge on a recently described entity.","authors":"Antonio Travaglino, Damiano Arciuolo, Susanna Ronchi, Antonio Raffone, Isabella Giovannoni, Sabina Barresi, Jvan Casarin, Gian Franco Zannoni, Rita Alaggio, Stefano La Rosa","doi":"10.1007/s00428-025-04127-0","DOIUrl":"https://doi.org/10.1007/s00428-025-04127-0","url":null,"abstract":"Endometrial stromal tumors with whorling and CTNNB1 rearrangement (ESTW-CTNNB1) are recently described gynecological mesenchymal neoplasms with unique clinicopathological and molecular features. To date, only four of these tumors have been reported. Herein, we describe a case of ESTW-CTNNB1 in a 67-year-old woman. The tumor measured 10 cm and had well-defined margins. On histology, the neoplasm was mostly composed of whorls of epithelioid cells immersed in a loose fibroblastic background, with a delicate vasculature and focal sex cord-like pattern. Tumor cells were mildly atypical, and mitotic index was < 1/10HPF. The tumor showed areas of ischemic necrosis and hydropic changes; no coagulative tumor cell necrosis was observed. On immunohistochemistry, tumor cells were diffusely positive for β-catenin (nuclear), CD10, WT1, calretinin, SATB2, estrogen, and progesterone receptor and negative for CDX2, CK8/18, and p63, with Ki67 = 10%. Molecular analysis revealed a GREB1::CTNNB1 fusion. In conclusion, we reported we 5th case of ESTW-CTNNB1, confirming the previously described features and highlighting positivity for SATB2.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CD34-positive pleomorphic uterine sarcoma with NUDT3::RAD51B fusion. cd34阳性多形性子宫肉瘤伴NUDT3::RAD51B融合。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2025-05-14 DOI: 10.1007/s00428-025-04126-1

Xiaona Yin, Lin Ye, Jiayun Xu, Ming Zhao

{"title":"CD34-positive pleomorphic uterine sarcoma with NUDT3::RAD51B fusion.","authors":"Xiaona Yin, Lin Ye, Jiayun Xu, Ming Zhao","doi":"10.1007/s00428-025-04126-1","DOIUrl":"https://doi.org/10.1007/s00428-025-04126-1","url":null,"abstract":"Sarcomas with RAD51B fusions are rare, recently recognized neoplasms that predominantly arise in the uterus. They showed heterogeneous phenotypic features and are typically associated with aggressive biological behaviors. To date, only 14 cases of RAD51B-rearranged sarcomas have been reported in English literature, including 6 perivascular epithelioid cell tumors, 6 leiomyosarcomas, and 2 undifferentiated sarcomas (both uterine in origin). We present an additional case of uterine sarcoma with RAD51B rearrangement. The patient was a 71-year-old woman with a 5.0-cm polypoid mass in the uterine cavity. Histologically, the tumor was composed of spindle to pleomorphic cells arranged in storiform and fascicular patterns within variably myxoid and collagenous stroma. The neoplastic cells had vesicular to hyperchromatic nuclei with occasional multinucleation, with a mitotic rate of 3/10 high-power fields. Notable stromal features included staghorn shaped blood vessels, thick band-like collagen deposition, and prominent chronic inflammatory infiltrates. Immunohistochemically, the tumor cells showed diffuse and strong positivity for CD34, P53, and P16, with focal expression of pan-TRK and smooth muscle actin. Targeted RNA-sequencing revealed NUDT3::RAD51B fusion, which was confirmed by fluorescence in situ hybridization of RAD51B rearrangement. The patient had been free of disease at 22 months' follow-up. This case further illustrates the phenotypic heterogeneity of RAD51B-rearranged sarcomas and expands their clinicopathological and molecular genetic spectrum.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144020849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Screening at the scope: enhancing the role of pathologists in diagnosing gastrointestinal polyposis syndromes. 范围筛查：增强病理学家在胃肠道息肉综合征诊断中的作用。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2025-05-13 DOI: 10.1007/s00428-025-04118-1

Pari Jafari, Christine Drogan, Emma Keel, Sonia Kupfer, John Hart, Namrata Setia

{"title":"Screening at the scope: enhancing the role of pathologists in diagnosing gastrointestinal polyposis syndromes.","authors":"Pari Jafari, Christine Drogan, Emma Keel, Sonia Kupfer, John Hart, Namrata Setia","doi":"10.1007/s00428-025-04118-1","DOIUrl":"https://doi.org/10.1007/s00428-025-04118-1","url":null,"abstract":"Only a minority of patients at high likelihood of a gastrointestinal polyposis syndrome (GPS) are appropriately referred for workup. This proof-of-concept study evaluates a GPS screening rubric based exclusively on information in prior pathology reports and intended to facilitate pathologist engagement in GPS screening and referral. We sought to (1) identify patients who would benefit from further GPS workup, (2) assign a probable polyposis syndrome category (adenomatous, hamartomatous, serrated, or mixed), and (3) suggest a specific syndrome, such as familial adenomatous polyposis, whenever possible. We retrospectively tested the rubric against the pathology records of 108 patients (median, 6 reports/patient) with an established clinical diagnosis of GPS (adenomatous (N = 88), hamartomatous (N = 18), and mixed (N = 2) polyposis syndromes). Records were reviewed chronologically (mean, 4.4 min/patient) by a GI pathologist blinded to clinical history. Ninety-five patients (88%) had a positive GPS screen (N = 76 with an adenomatous polyposis syndrome, N = 17 with a hamartomatous polyposis syndrome, N = 2 with a mixed polyposis syndrome); all were assigned to the correct syndrome category. In a subset of cases, the histopathologic record suggested a specific syndrome (correct in 28 of 30 instances). Of 13 patients with a negative screen (failure to meet any rubric parameters), N = 6 (46.2%) had incomplete records. These findings demonstrate that when robust records are available, structured review of pathology reports is a sensitive and efficient tool for the identification of patients with a high suspicion of a GPS. While prospective studies are necessary, pathologists are indeed well positioned to play an expanded role in GPS screening.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of an automated artificial intelligence-based tool for reticulin fibrosis assessment in bone marrow biopsies. 开发一种基于人工智能的自动化工具，用于骨髓活检中网状蛋白纤维化的评估。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2025-05-13 DOI: 10.1007/s00428-025-04122-5

Giuseppe D'Abbronzo, Antonio D'Antonio, Annarosaria De Chiara, Luigi Panico, Lucianna Sparano, Anna Diluvio, Antonello Sica, Gino Svanera, Giovanni De Chiara, Mariano Fuggi, Ferdinando Russo, Renato Franco, Andrea Ronchi

{"title":"Development of an automated artificial intelligence-based tool for reticulin fibrosis assessment in bone marrow biopsies.","authors":"Giuseppe D'Abbronzo, Antonio D'Antonio, Annarosaria De Chiara, Luigi Panico, Lucianna Sparano, Anna Diluvio, Antonello Sica, Gino Svanera, Giovanni De Chiara, Mariano Fuggi, Ferdinando Russo, Renato Franco, Andrea Ronchi","doi":"10.1007/s00428-025-04122-5","DOIUrl":"https://doi.org/10.1007/s00428-025-04122-5","url":null,"abstract":"Bone marrow fibrosis plays a critical role in the diagnosis, prognosis, and management of haematological disorders, particularly myeloproliferative neoplasms like primary myelofibrosis. Accurate assessment of fibrosis, typically graded through histochemical techniques such as reticulin and trichrome staining, is essential but remains highly dependent on the pathologist's experience. To address the challenges of variability in interpretation and the increasing demand for standardized evaluations, we developed a digital pathology system for automated bone marrow reticulin fibrosis grading. This study utilized 86 bone marrow biopsy specimens from patients diagnosed with Philadelphia chromosome-negative myeloproliferative neoplasms, collected between 2018 and 2023. A fully convolutional network based on the InceptionV3 architecture was trained to assess fibrosis grades (MF0-MF3) from whole slide images of reticulin-stained sections. The model was trained using 3814 annotated images and validated using a separate set of 40 BMBs. The algorithm's performance was evaluated by comparing its fibrosis grading to expert hematopathologists' assessments, yielding a Cohen's kappa coefficient of 0.831, indicating excellent agreement. The algorithm showed strong concordance in fibrosis grading, especially for MF0 (k = 0.918) and MF3 (k = 0.886), and substantial agreement for intermediate grades (MF1 and MF2). Further validation across multiple institutions and scanning platforms confirmed the algorithm's robustness, with an overall agreement of 0.816. These results demonstrate the potential of digital pathology tools to provide standardized, reproducible fibrosis grading, thereby aiding pathologists in clinical decision-making and training.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlation between basal cell adenoma and basal cell adenocarcinoma of the salivary gland: a histomorphological and molecular review of 129 cases. 唾液腺基底细胞腺瘤与基底细胞腺癌的相关性：129例组织形态学和分子复习。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2025-05-13 DOI: 10.1007/s00428-025-04120-7

Haruna Yagi, Yoshitaka Utsumi, Yuichiro Tada, Satoshi Baba, Toshihide Iwashita, Kennosuke Karube, Makoto Urano, Toshitaka Nagao, Masato Nakaguro

{"title":"Correlation between basal cell adenoma and basal cell adenocarcinoma of the salivary gland: a histomorphological and molecular review of 129 cases.","authors":"Haruna Yagi, Yoshitaka Utsumi, Yuichiro Tada, Satoshi Baba, Toshihide Iwashita, Kennosuke Karube, Makoto Urano, Toshitaka Nagao, Masato Nakaguro","doi":"10.1007/s00428-025-04120-7","DOIUrl":"https://doi.org/10.1007/s00428-025-04120-7","url":null,"abstract":"Basal cell adenoma (BCA) and basal cell adenocarcinoma (BCAC) are salivary gland tumors with biphasic differentiation, composed of luminal ductal cells and abluminal basal cells with a high nuclear-to-cytoplasmic ratio. While BCA is a relatively common benign tumor, BCAC is a rare malignancy, and its genetic context and relationship with BCA remain unclear. We investigated 93 BCA and 36 BCAC cases to further characterize these two tumor entities from histological and molecular perspectives. BCA/BCAC proliferated in a mixture of tubular, trabecular, solid, cribriform, and membranous patterns. A jigsaw puzzle pattern, peripheral palisading, S100-positive stroma, cystic change, and sclerosis were observed in approximately 50% of the cases. BCAC demonstrated the following malignant features: infiltration to surrounding tissue, tumor necrosis, and increased mitotic activity (81%, 22%, and 22%, respectively). The nuclear expression of β-catenin was frequently observed in both BCA and BCAC (89% and 60%), and CTNNB1 hotspot mutations were detected in 46% and 48% of BCA and BCAC cases, respectively. Tubular patterns of growth, jigsaw puzzle patterns, peripheral palisading, S100-positive stroma, and cystic changes were more common in β-catenin-positive BCA/BCAC than in β-catenin-negative BCA/BCAC. Among the β-catenin-negative BCA/BCAC cases, one case each harbored PLAG1 and MYB rearrangements. We concluded that β-catenin-positive BCA and BCAC share common histologic and molecular features, and BCAC is considered a malignant counterpart of BCA. β-Catenin-negative BCA/BCAC might include morphological mimickers, which can be genetically classified into other tumor types, including pleomorphic adenoma and adenoid cystic carcinoma.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utilization of NKX3.1 and P501S to distinguish primary breast carcinoma from metastatic prostatic adenocarcinoma in male patients. 应用NKX3.1和P501S鉴别男性原发性乳腺癌和转移性前列腺腺癌。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2025-05-10 DOI: 10.1007/s00428-025-04124-3

Mustafa Goksel, Chirag R Patel, Sarah A Anderson, Gian Piero Carames, Sandra S Moultrie, Cristina Magi-Galluzzi, Shi Wei, Xiao Huang

{"title":"Utilization of NKX3.1 and P501S to distinguish primary breast carcinoma from metastatic prostatic adenocarcinoma in male patients.","authors":"Mustafa Goksel, Chirag R Patel, Sarah A Anderson, Gian Piero Carames, Sandra S Moultrie, Cristina Magi-Galluzzi, Shi Wei, Xiao Huang","doi":"10.1007/s00428-025-04124-3","DOIUrl":"https://doi.org/10.1007/s00428-025-04124-3","url":null,"abstract":"NKX3.1 is an androgen-regulated tumor suppressor gene, and NKX3.1 protein expression is present mainly in prostatic epithelium. P501S is expressed in prostatic epithelium and is also regulated by androgens. Immunohistochemistry (IHC) for NKX3.1 and P501S is commonly used for the diagnosis of metastatic prostate carcinoma in pathology practice. Male breast cancer is rare, and most of the tumors are androgen-receptor positive. Thus, we investigated NKX3.1 and P501S expression in male breast carcinoma to determine its role in distinguishing primary breast carcinoma from metastatic prostatic adenocarcinoma. IHC for NKX3.1 and P501S was performed on primary invasive breast carcinomas in 25 male patients, 5 of whom had prior history of prostatic adenocarcinoma. Immunoreactivity was classified as negative or positive staining. Expression of NKX3.1 and P501S was identified in 8 (32%) and 7 (28%) cases of invasive breast carcinomas, 42% and 20% of in situ breast carcinomas, and 8% and 46% of normal terminal ductal lobular unit (TDLU), respectively. Among the five patients with prior history of prostate carcinoma, four had NKX3.1 or P501S expression in their primary invasive breast carcinomas. Their diagnosis of primary invasive breast carcinomas was confirmed by GATA3 and estrogen receptor (ER) IHC. This is the first study to report NKX3.1 and P501S expression in primary breast carcinomas in male patients. The positive rates are higher than those reported in female patients with ductal carcinoma. When considering the use of IHC markers to confirm the diagnosis of primary breast carcinoma in male patients, breast-specific markers or hormonal receptors should be considered in the diagnostic panel.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0